{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03728556","nct_id":"NCT03728556","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03728556. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"CS1001monoclonal antibody","type":"EXPERIMENTAL"},{"description":null,"label":"CS1001 Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-04-03","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer Stage III"],"enrollment":{"count":381,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CS1001 monoclonal antibody","otherNames":[],"type":"BIOLOGICAL"},{"name":"CS1001 placebo","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2023-06-15","lead_sponsor":"CStone Pharmaceuticals","official_title":"A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Has Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-04-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progress Free Survival (PFS)","timeFrame":"from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months."}],"references":[{"citation":"Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14.","pmid":"35038429","type":"DERIVED"}],"start_date":{"date":"2018-10-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03728556"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03728556"}